A detailed history of Black Rock Inc. transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Black Rock Inc. holds 698,267 shares of AIM stock, worth $174,566. This represents 0.0% of its overall portfolio holdings.

Number of Shares
698,267
Previous 698,333 0.01%
Holding current value
$174,566
Previous $328,000 21.34%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.35 - $0.61 $23 - $40
-66 Reduced 0.01%
698,267 $258,000
Q1 2024

May 10, 2024

SELL
$0.33 - $0.48 $3,126 - $4,547
-9,473 Reduced 1.34%
698,333 $328,000
Q4 2023

Feb 13, 2024

BUY
$0.4 - $0.56 $64 - $89
160 Added 0.02%
707,806 $311,000
Q3 2023

Nov 13, 2023

BUY
$0.44 - $0.71 $44 - $72
102 Added 0.01%
707,646 $325,000
Q2 2023

Aug 11, 2023

SELL
$0.4 - $0.67 $43,833 - $73,420
-109,583 Reduced 13.41%
707,544 $474,000
Q1 2023

May 12, 2023

BUY
$0.32 - $0.77 $1,088 - $2,618
3,401 Added 0.42%
817,127 $351,000
Q4 2022

Feb 13, 2023

BUY
$0.31 - $0.6 $82 - $159
266 Added 0.03%
813,726 $252,000
Q3 2022

Nov 14, 2022

SELL
$0.57 - $0.81 $1,847 - $2,626
-3,242 Reduced 0.4%
813,460 $473,000
Q2 2022

Aug 12, 2022

SELL
$0.78 - $1.27 $9,235 - $15,038
-11,841 Reduced 1.43%
816,702 $638,000
Q1 2022

May 12, 2022

SELL
$0.67 - $1.18 $3,859 - $6,796
-5,760 Reduced 0.69%
828,543 $878,000
Q4 2021

Feb 10, 2022

BUY
$0.92 - $1.96 $5,653 - $12,044
6,145 Added 0.74%
834,303 $767,000
Q3 2021

Nov 09, 2021

BUY
$1.91 - $2.17 $10,443 - $11,865
5,468 Added 0.66%
828,158 $1.67 Million
Q2 2021

Aug 11, 2021

BUY
$1.93 - $2.39 $1.59 Million - $1.97 Million
822,690 New
822,690 $1.77 Million

Others Institutions Holding AIM

About AIM ImmunoTech Inc.


  • Ticker AIM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,049,300
  • Market Cap $12M
  • Description
  • AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...
More about AIM
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.